Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) China Market Research Report 2021-2025 – ResearchAndMarkets.com

0

DUBLIN–(BUSINESS WIRE)–The “China PEGylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) Survey Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.

PEGylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) is an effective drug for the prevention and treatment of neutropenia or deficiency caused by radiotherapy or tumor chemotherapy. Its product was first developed by Amgen in the United States.

In 2012, PEG-rhG-CSF was approved in China. By 2020, the key PEG-rhG-CSF manufacturers in China are Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd.

According to the market research, the sales of PEG-rhG-CSF in the Chinese market increased year on year from 2016 to 2020. Among them, the sales growth in 2017 was the most obvious, from 126 million CNY in 2016 to CNY 449 million in 2017, with an annual growth rate of 256.08%.

The main reason for this large increase is that PEG-rhG-CSF was included in Chinese medical insurance in 2017 and the indication was leukemia. Lower prices led to a sharp increase in sales. The sales CAGR of PEG-rhG-CSF is approximately 97.58% from 2016 to 2020.

The analyst analyzes that the sales volume of PEG-rhG-CSF will maintain a growth trend from 2021 to 2025 due to the rapid increase in the number of patients. In China, about 40,000 leukemia patients are newly diagnosed each year. This situation has led to a growth in the sales volume of PEG-rhG-CSF, which has the advantages of convenience, stability, high efficacy and indication approval.

In addition, due to the use of PEG-rhG-CSF for nonmedullary malignancies, the number of indications approved for Chinese medical insurance is likely to increase, and sales and sales volume will also the potential to grow.

Topics Covered:

  • The impact of COVID-19 on China’s PEGylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) Market

  • Sales Value of China PEGylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2016-2020

  • Competitive landscape of China PEGylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) Market

  • PEGylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) Price in China

  • Price of PEGylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China by Regions and Manufacturers

  • Analysis of factors affecting the development of China market of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF)

  • China Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) Market Outlook 2021 to 2025

Main topics covered:

1 Relevant Concepts of PEGylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF)

1.1 Indications for PEGylated Recombinant Human Granulocyte Colony Stimulating Factor

1.2 Development of PEGylated Recombinant Human Granulocyte Colony Stimulating Factor in China

1.3 Government Approval of PEGylated Recombinant Human Granulocyte Colony Stimulating Factor in China

1.4 COVID-19’s impact on China PEGylated Recombinant Human Granulocyte Colony Stimulating Factor Sales

2 China PEGylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, 2016-2020

2.1 Business Value of PEGylated Recombinant Human Granulocyte Colony Stimulating Factor

2.1.1 Overall sales value

2.1.2 Sales Value by Regions

2.2 PEGylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 China PEGylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 Analysis of PEGylated Recombinant Human Granulocyte Colony Stimulating Factors Key Manufacturers in China 2016-2020

3.1 Key Manufacturers Market Share Analysis of PEGylated Recombinant Human Granulocyte Colony Stimulating Factors

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd.

3.2.1 Company profile

3.2.2 China Jinyouli (Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd.’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor) Sales

3.3 Qilu Pharmaceutical Co., Ltd.

3.3.1 Company Profile

3.3.2 China Xinruibai (Pegylated Recombinant Human Granulocyte Colony Stimulating Factor from Qilu Pharmaceutical Co., Ltd.) Sales

4 PEGylated Recombinant Human Granulocyte Colony Stimulating Factor Price for Different Manufacturers in China, 2020-2021

4.1 Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. (Yinish)

4.2 Qilu Pharmaceutical Co., Ltd. (Xinruibai)

5 China PEGylated Recombinant Human Granulocyte Colony Stimulating Factor Market Outlook, 2021-2025

5.1 Influencing Factors of Chinese PEGylated Recombinant Human Granulocyte Colony Stimulating Factor Market Development

5.1.1 The impact of COVID-19 on China’s PEGylated Recombinant Human Granulocyte Colony Stimulating Factor Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

Companies cited

  • Shiyao Baike Group biopharmaceutical Co., Ltd.

  • Qilu Pharmaceutical Co.,Ltd

For more information on this report, visit https://www.researchandmarkets.com/r/5flris

Share.

Comments are closed.